Filed Pursuant to Rule 424(b)(3)
                                                Registration No. 333-59798


                               CEL-SCI CORPORATION

                              Prospectus Supplement
                       (To Prospectus Dated May 24, 2002)

     Prospective  investors  should  read  this  prospectus  supplement  and the
related  prospectus  carefully before investing in CEL-SCI's common stock.  Both
documents contain information  prospective investors should consider when making
an investment decision.

     The attached  prospectus  relates to the resale of shares  acquired by Paul
Revere Capital Partners, Ltd. pursuant to an equity line of credit. Because Paul
Revere  Capital  Partners may sell some or all of these shares,  and since there
are currently no agreements,  arrangements or understandings with respect to the
sale of any of these shares, CEL-SCI cannot estimate the actual number of shares
that Paul  Revere  Capital  Partners  will  hold  after  the  completion  of the
offering.

     The following provides information concerning the latest drawdown requested
by CEL-SCI.

    Date of       Shares          Average Sale             Net Proceeds
      Sale         Sold          Price Per Share            to Cel-Sci
    --------       -----          ---------------         ------------------

    03/05/03      56,483               $0.16                  $  8,091

     The proceeds to CEL-SCI are net of a $1,000 fee paid to an escrow agent.

     CEL-SCI's  common stock is quoted on the American  Stock Exchange under the
symbol  "CVM".  On March 5, 2003 the  closing  price for one share of  CEL-SCI's
common stock was $0.17.

     CEL-SCI  expects  to use the  proceeds  from the sale of these  shares  for
general and administrative expenses, research and clinical trials.



            The date of this prospectus supplement is March 5, 2003.